Sanofi Removes CEO Paul Hudson after Vaccine Turnaround Stalls
Sanofi has removed CEO Paul Hudson after five years of underwhelming vaccine revenue growth and stalled group turnaround since 2019. The NIH discontinued the low-dose rivaroxaban arm of J&J’s Phase 3 CAPTIVA stroke prevention trial following safety concerns and low likelihood of benefit.
1. Sanofi CEO Ousted
On February 12 Sanofi’s board dismissed CEO Paul Hudson after five years of stagnant vaccine sales growth and missed strategic targets, initiating an executive search to reset leadership and revitalize its product pipeline.
2. Trial Safety Review Stops Rivaroxaban Arm
The NIH directed all sites to cease the low-dose rivaroxaban arm of its Phase 3 CAPTIVA stroke prevention trial after an independent safety review detected elevated bleeding events and concluded the treatment was unlikely to demonstrate clinical benefit.